RxDoctor Payments Data

Mark Jones, MD

Cardiovascular Disease · Indianapolis, INNPI 1801867346

Payments from drug & device makers

$1,386in general payments, 2019–2025

Across 42 payments — averaging $32.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$594
  • Akcea Therapeutics, Inc.$156
  • E.r. Squibb & Sons, L.L.C.$147
  • Boston Scientific$136
  • Amgen$80
  • Johnson & Johnson$58
  • plus $214 from 10 others

What the payments were for

  • Travel & lodging$46734%
  • Food & beverage$91966%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,386 in reported general payments places this provider in the 35th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$122,126
Medicare patients
994
Services billed
1,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban524$703,574
EntrestoSacubitril/Valsartan230$291,785
XareltoRivaroxaban152$191,507
JardianceEmpagliflozin88$97,945
Repatha SureclickEvolocumab79$89,475
VascepaIcosapent Ethyl37$33,731
BrilintaTicagrelor16$19,575
Metoprolol Succinate725$9,739
Atorvastatin Calcium992$8,474
Ezetimibe388$7,843
Diltiazem 24hr Er (Cd)Diltiazem Hcl199$7,305
Ranolazine ErRanolazine48$6,292
Carvedilol646$4,971
ClopidogrelClopidogrel Bisulfate427$4,745
Losartan Potassium424$4,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$703,574524 claims
NovartisEntresto$36$291,785230 claims
Johnson & JohnsonXarelto$58$191,507152 claims
AstraZenecaBrilinta$14$19,57516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →